Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease
- Urgent need for clinical trials of interventions designed to decrease levels of these middle molecules in CKD patients
This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative
We deliver and support renal therapies across the continuum of care, including the innovative HDx.
TherapiesOrgan support and blood purification therapies are essential to improving patient outcomes in the ICU.
Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.
Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.
HDx - also known as expanded hemodialysis - is an innovative therapy that effectively targets the removal of large middle molecules.
Learn more about Baxter’s key products for Renal Care – across the continuum of care.
Acute Therapy
Peritoneal Dialysis
Groundbreaking research and inspirational patient stories.
Explore the research enabling innovative Renal Care.
Patients’ journeys inspire our work and drive our commitment.
Access resources for Baxter’s broader Renal Care portfolio.
This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative